Results
H uman ApoE is a polymorphic multifunctional protein arising from three alleles at a single gene locus. However, a common mode of action of ApoE in physiology and disease has not been identified [1] [2] [3] [4] [5] [6] [7] . The human isoforms of ApoE, ApoE2, ApoE3, and ApoE4, differ by amino acid residues 112 and 158 located outside of the N-terminal receptor-binding site, yielding proteins with distinct impacts on tissue homeostasis. Thus, ApoE may act through multiple pathways depending on its isoform, cellular source, the lipid moieties it binds, and multiple genetic and environmental risk factors. Notions regarding mechanisms of action of ApoE include isoform-specific domain-domain interactions 7 ; involvement of lipoprotein receptors 2, 3 ; effects on cholesterol efflux 7 ; maintenance of the blood-brain barrier (BBB) 1, 6 ; and binding extracellular molecules, including beta amyloid peptide and heparan sulfate proteoglycans 2 . This wide range of activities indicates that ApoE exercises its functions in complex territorialized tissue contexts. Here, we explored the roles of ApoE in the aging ChP, brain, and the aorta of mice and in two major prototypic human unresolvable diseases, that is, Alzheimer's disease (AD) and atherosclerosis. We chose these diseases because both have been linked to ApoE: AD is the most common form of dementia, and the ApoE4 isoform predisposes to late onset AD (LOAD) 2, 3 . Atherosclerosis is the leading cause of death worldwide 8, 9 . Our data indicate that ApoE is a CCC checkpoint inhibitor by binding to activated C1q and that the resulting C1q-ApoE complex emerges as a common player to impact brain inflammation and atherosclerosis. ChPs and associated parenchyma per tissue area were quantified as described in Methods (b). WT (n = 3 mice); ApoE −/− (n = 9); ND ApoE3 (n = 6); HFD ApoE3 (n = 6); ND ApoE4 (n = 6); HFD ApoE4 (n = 9). c, Plasma cholesterol. WT (n = 6); ApoE −/− (n = 6); ApoE3 (n = 14); ApoE3 HFD (n = 17); ApoE4 (n = 8); ApoE4 HFD (n = 10) mice. d, Epithelial cells were stained for cytokeratin (keratin, red), leukocytes (CD45, green), and nuclei with DAPI (blue). Phase contrast delineates the ChP. Dashed line indicates the border of ChP and the ventricle. Scale bar, 100 µ m. e, CD68 + areas were quantified as described in Methods. 12 sections from 4 WT mice; 12 sections from 4 ApoE −/− mice. f, ChPs were stained for lipid with BODIPY (BO, green), endothelial cells (CD31, cyan), and macrophages (Iba-1, red) (left panel). TEM shows a single ChP macrophage-foam cell (middle panel) and lipid (BO, green) and immunoglobulin (Ig, red) (right panel). Scale bars, 10 μ m. g, IFN-related genes in ChPs by microarray. Heat maps show two-group comparisons of ChPs. The percentages of up-and downregulated genes are shown in the pie charts. h, ApoE4isoform-dependent IFN signature expression in ChPs. WT (n = 5 mice); ApoE −/− (n = 4); ND ApoE3 (n = 6); HFD ApoE3 (n = 6); ND ApoE4 (n = 6); HFD ApoE4 (n = 6). Data in d,f are representative images from at least three biologically independent mouse samples. Data in b,c,e,h represent means ± s.e.m. Two-tailed Student's t test was applied for P values in b,c,e; one-way ANOVA with Tukey's test was applied to h. ChP, choroid plexus; V, ventricle; Ep, epithelial cells; Nu, nucleus; Va, vacuole; TJ, tight junction. Gene names and statistics are in Supplementary Tables 2 and 3 .
Articles NATuRE MEDiCiNE accumulated in the perivascular space of the lipid-free brain parenchyma of ApoE −/− and NC or HFD ApoE4-KI mice, thus confirming the findings of Bell et al. 1 . However, there was no statistically discernable aggravation of BBB dysfunction as a function of hyperlipidemia (Extended Data Fig. 1e ).
In view of the morphological ChP phenotypes in WT, ApoE −/− and ApoE-KI mice ( Fig. 1 and Extended Data Fig. 1 ), we decided to examine differential ChP gene expression profiles in six groups of mice: WT, ApoE −/− , ND-or HFD-fed ApoE3-KI, and NC or HFD-fed ApoE4-KI mice. For this purpose, laser capture microdissection-based MIAME-compliant microarrays (https://www.ncbi. nlm.nih.gov/geo/; accession nos.: GSE85774 and GSE85775) from ChPs of various mouse groups were examined. 241 differentially expressed ChP genes in the six transcriptomes were identified in gene ontology (GO) terms 'immune system process' , 'transcription factor binding' , 'cell junction' , and ' ATP binding' (Extended Data Fig. 1f and Supplementary Table 1 ). In ApoE −/− ChPs, most (81%) differentially expressed genes were downregulated compared with those in WT ChPs (Fig. 1g ); however, 58% (7/12) of upregulated genes were interferon (IFN)-related genes, with none downregulated ( Fig. 1g ). NC-fed ApoE4 replacement ChPs further induced (44%, 22/50) IFN-related genes ( Fig. 1g ). Multiple two-group comparisons revealed a pronounced ApoE4-specific ChP IFN signature ( Fig. 1g and Supplementary Table 2 ). The biological activities of the IFN-related genes range from regulation of autoimmunity by macrophages and DCs to BBB integrity including IFN-induced protein with tetratricopeptide repeats 3 and 1 (ifit3, ifit1), ubiquitinspecific peptidase 18 (usp18), guanylate-binding protein 3 (gbp3), interferon-induced protein 44 (ifi44), receptor transporter protein 4 (rtp4), IFN-regulatory factor 7 (irf7), and interferon, alpha-inducible protein 27-like 2A (ifi27l2a) (Fig. 1h ). These data provided evidence for a detrimental and isoform-specific impact of ApoE4 in ChP homeostasis, as ChP IFN has been associated with cognitive decline 15 . Moreover, several genes that were downregulated in ApoE −/− ChPs were rescued in their ApoE-KI counterparts, indicating phenotypic ChP changes specific for ApoE deficiency (Extended Data Fig. 1g ). Additionally, complement genes were observed to be upregulated in ApoE −/− ChPs (Fig. 2 , Extended Data Fig. 2 , and Supplementary Table 3 ).
Complement-triggered ChP inflammation is attenuated by C5
siRNA. It is well recognized that oxidation-specific epitopes in extracellular lipid bind Igs and activate complement 16, 17 , and complement activation results in surface opsonization by C3b; generation of locally acting anaphylatoxins, that is, C3a and C5a; and subsequent recruitment of leukocytes and tissue inflammation 18 . We hypothesized that the lipid deposits in ApoE −/− ChPs bind Igs with resultant activation of complement. Igs, C3, C3a, and C5 were evident together with lipid in ChPs of ApoE −/− mice, but not in WT mice ( Fig. 2a,b ). The CCC-initiating C1q molecule and C4 colocalized with ChP lipid deposits (Extended Data Fig. 2a ). Most complement constituents are produced by the liver and released into the circulation as inactive components, or they can be produced locally in tissues. Whereas several complement components were significantly expressed in the ChP, C5 transcripts were below the threshold level in ChP transcriptomes, indicating that ChP C5 was largely serum-and liver-derived (not shown). To examine whether ChP lipid-triggered CCC activation participates in leukocyte infiltration, we chose to specifically target liver-derived C5 using an siRNA that is exclusively taken up by the liver using an asialoglycoprotein receptor-specific tag, that is N-acetylgalactosamine (GalNAc) C5 siRNA ( Fig. 2c ). Liver C5 siRNA knockdown in ApoE −/− mice led to a large decrease of circulating C5 levels ( Fig. 2c ), without affecting blood lipoprotein concentrations, body weight, or circulating leukocytes (data not shown). Liver-targeted C5 silencing also resulted in substantial decrease of C5 protein deposits in the ChP (Extended Data Fig. 2b ) and significantly attenuated CD45 + leukocyte, CD68 + macrophage and DC, and CD3 + T cell infiltration in ApoE −/− ChPs ( Fig. 2d-f ). In contrast, IgG, C4, and C3 deposition were much less affected (Extended Data Fig. 2b,c) . These data demonstrated that lipid-triggered complement cascade activation promoted ChP leukocyte infiltration. However, C3 and C4 were present at much lower levels in HFD ApoE4-KI ChPs versus ApoE −/− ChPs (Fig. 2g ), despite similar amounts of ChP lipid (parallel sections from Fig. 1c ) and respective serum C3 and C5 levels (Extended Data Fig. 2d ), thus indicating that the presence of ApoE in the ChP prevented the marked complement cascade phenotype of ApoE −/− ChPs. ApoE colocalized with Igs and C1q ( Fig. 2h and Extended Data Fig. 2e ). Using an unbiased gene expression approach, that is, expression microarrays, we examined all complement-related gene signatures in ChPs. We identified six transcripts encoding CCC-specific constituents (c1qa, c1qb, c1qc, c2, c3ar1, C1ra), which were selectively upregulated in ChPs of ApoE −/− mice compared with WT mice ( Fig. 2i and Extended Data Fig. 2f ). Subsequent to CCC activation, C3b (cleavage product of C3) initiates a constitutive amplification loop of the alternative complement cascade. Factor H (alternative complement pathway inhibitor) mRNA was detectable without differences between groups (Extended Data Fig. 2g ); factor B and MASP1 (components of the alternative and lectin pathways of complement activation) transcripts were below threshold levels. However, factor H protein accumulation was observed on lipid deposits of both ApoE −/− and HFD ApoE4 ChPs (Extended Data Fig. 2h ), indicating the presence of a C3b-initiated amplification loop that recruited factor H in both groups of mice. Interestingly, C1qa and C1qc transcripts were rescued in ApoE-KI versus ApoE −/− ChPs (Fig. 2i ), and various complement regulators were expressed in ApoE −/− and ApoE-KI ChPs (Extended Data Fig. 2f ). Taken together, these data revealed pronounced CCC activation in ApoE −/− but not in HFD ApoE3-KI, and less in HFD-fed ApoE4-KI mice. Additionally, we found that ApoE mRNA ranges in the top 50 of ~14,000 genes expressed in WT ChPs, indicating that ApoE is expressed at extraordinarily high levels in normal ChPs, ranging in expression in > 99 % of all expressed ChP genes ( Supplementary Table 4 ).
ApoE inhibits CCC activity. The salient absence or low expression of key complement components in HFD ApoE4-KI ChPs led us to examine a role of ApoE in the classical, alternative, and lectin pathways 18 . ApoE was added to normal human serum (NHS), which was activated by pathway-specific buffers, and incubated with non-human erythrocytes, and lysis of erythrocytes was determined. All three variants, ApoE2, ApoE3, and ApoE4, reduced CCC activation, but not the alternative pathway ( Fig. 3a ). Furthermore, in a complement-mediated killing assay, Escherichia coli remained viable upon ApoE-supplemented NHS challenge, but were killed when complement was activated via the lectin or alternative pathways ( Fig. 3b ), indicating that ApoE inhibits CCC activity, but not the alternative or lectin pathways. All three ApoE isoforms inhibited deposition of C4b and the terminal complement complex (TCC) by ~80% ( Fig. 3c) , showing that ApoE acts early in CCC activation. Oxidized low-density lipoprotein (oxLDL) has been reported to activate the CCC 19 ; we found that purified C1q indeed bound malondialdehyde-modified LDL (MDA-LDL) and oxLDL, but not native LDL (Extended Data Fig. 3a ). Moreover, ApoE inhibited the CCC and reduced C4b deposition when the CCC was activated by MDA-LDL (Extended Data Fig. 3b ). Notably, amyloid fibrils but not soluble amyloid triggered C3b deposition, thus reflecting complement activation (Extended Data Fig. 3c,d) .
ApoE inhibits the CCC by high-affinity binding to the stalk of activated C1q. During CCC initiation, C1q is activated by undergoing a conformational change in a Ca 2+ -dependent manner. Proteases C1s and C1r then bind to the activated C1q, forming the Articles NATuRE MEDiCiNE C1 complex, then C2 and C4 are cleaved to form the C3 convertase C4b2b 18 . We incubated ApoE3 with C2 or C4 in the presence of the protease C1s. However, ApoE3 failed to inhibit C2 or C4 cleavage by C1s (Extended Data Fig. 3e ,f). ApoE3 also lacked cofactor activity for factor I-mediated degradation of C4b (Extended Data Fig. 3g ). ApoE binding to complement proteins revealed strong binding to C1 and C1q, but not to C1r, C1s, C2, C3, C3b, or C4 ( Fig. 3d and Extended Data Fig. 4a -c). ApoE also bound factor H (Extended Data Fig. 4c ), extending an earlier report of factor H binding to ApoE on plasma high-density lipoprotein 20 . However, ApoE did not inhibit the alternative complement pathway ( Fig. 3a,b ). All three recombinant ApoE isoforms and serum-derived ApoE3 bound C1 and C1q (Extended Data Fig. 4d,e ). Binding of C1q to immobilized ApoE was further confirmed (Extended Data Fig. 4f ), and we determined the strength of the interaction. All ApoE isoforms bound to C1q, and equilibrium dissociation constants ranged from ~140-580 pM ( Fig. 3e and Supplementary Table 5 ). The interaction with C1q was specific, as ApoE did not bind to mannan-binding lectin (MBL), a protein initiating the lectin pathway and sharing structural and functional features with C1q (Extended Data Fig. 4g ). Likewise, apolipoprotein A did not interact with C1q (Extended Data Fig. 4h ). C1q-ApoE complex formation was further confirmed by means of a proximity ligation assay (PLA) on cultured human apoptotic cells (Extended Data Fig. 4i ). ApoE isoforms bound to C1q in a Ca 2+ -dependent manner (Fig. 3f ), and EGTA reduced the binding of ApoE to C1q (Extended Data Fig. 5a ), indicating that ApoE selectively binds to the activated form but not the inactivated form of C1q. Activated C1q, but not the inactive serum C1q coimmunoprecipitated . g, Low C4 and C3 protein levels in lipid deposits of HFD ApoE4 ChPs. Serial sections of ChPs, as shown in Fig. 1a , were stained for C4 (green) and C3 (red). h, Super-resolution (STED) microscopy shows colocalization of C1q (green) and ApoE (red) in HFD ApoE4 ChPs. Scale bar, 10 μ m. i, ChP complement mRNA expression. WT (n = 4 mice); ApoE −/− (n = 5); ND ApoE3 (n = 6); HFD ApoE3 (n = 6); ND ApoE4 (n = 6); HFD ApoE4 (n = 6). Data in a,b,g,h are representative images from at least three independent mouse samples. Data represent means ± s.e.m. Two-tailed Student's t test was applied to c,d,e,f. ***P < 0.0001; one-way ANOVA with Tukey's test was applied to i. Gene names are in Supplementary Table 3 .
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ApoE and vice versa (Extended Data Fig. 5b ,c), suggesting that C1q-ApoE complexes are not present in serum.
To determine the binding site in ApoE to C1q, ApoE peptides were generated and examined for their ability to reduce ApoE4mediated CCC inhibition ( Fig. 4a ). ApoE peptide P 139-152 but not P [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] , P 74-85 , or P 210-232 abrogated CCC inhibition by ApoE4 ( Fig. 4b ), though P 139-152 alone did not inhibit CCC activity (data not shown). Analyzing binding of the four ApoE peptides to C1q revealed binding of P to C1q, but not of peptides P [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] , P 74-85 , or P 210-232 ( Fig. 4c ). Also, P 139-152 , but not P [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] competed with ApoE3 for binding to C1q (Extended Data Fig. 5d ). The dissociation constant K D of P 139-152 to C1q as assessed by MicroScale thermophoresis was ~500 pM (Fig. 4d ). These data imply that the C1q binding site in ApoE is located between residues 139-152, which also harbors the LDL receptor (LDLR) binding site (136-150) 21 . However, different binding forces for the LDLR and C1q in ApoE were indicated by the observation that the C1q-ApoE interaction was strongly reduced by SDS but not by NaCl, whereas LDLR-ApoE interaction was affected by NaCl but not by SDS (Fig. 4e ). The influence of SDS on antibody binding was excluded (Extended Data Fig. 5e ). Thus, ApoE binding to C1q was mediated by hydrophobic forces. Moreover, LDLR did not compete off C1q-ApoE binding (Extended Data Fig. 5f ), indicating that LDLR and C1q do not share the same binding site in ApoE. As monitored by electron microscopy, gold-labeled ApoE and goldlabeled ApoE 139-152 peptide revealed binding to the C1q stalk but not to the globular heads, which mediate target binding ( Fig. 4f ).
C1sC1r tetramers also bind to the C1q stalk 22 . However, ApoE and the C1sC1r tetramers do not share the same binding site in C1q, because the C1q-ApoE3 interaction was unaffected by C1sC1r tetramers in competition assays (Extended Data Fig. 5g ). These data revealed that ApoE acts as a specific CCC inhibitor by high-affinity binding to activated C1q at physiological concentrations.
ChP C1q-ApoE complexes correlate with cognitive decline.
Though ChP lipid deposits have not been reported in AD, we searched for pathologies in human AD ChPs that may resemble the pathology of ApoE −/− and HFD ApoE4-KI ChPs. We studied 30 age-and gender-matched human brains with various stages of AD-associated pathologies, that is, Braak & Braak stages for neurofibrillary tangles (NFTs) 23 , Thal phase for Aβ plaque score 24 , and the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) for neuritic plaque (Aß plaque with dystrophic neurites) burden ( Supplementary Table 6 ). 13/30 patients had no signs of dementia (Braak & Braak 0-III, Thal phase 0-5, CERAD stage 0), whereas 17/30 patients exhibited dementia upon clinical neurological examination and showed marked AD pathologies (Braak & Braak IV-VI, Thal phase 1-5, CERAD stage B-C) ( Supplementary Table 6) . Surprisingly, 29 of the 30 brains showed various degrees of ChP lipid deposits that were strikingly similar to those found in ApoE −/− and HFD ApoE4-KI ChPs (Fig. 5a ). Notably, cases with demented AD showed higher rates of lipid in ChPs versus those without dementia ( Fig. 5a ). Moreover, the burden of ChP lipid deposits correlated 
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with all AD neuropathologies ( Fig. 5b-d ), and the ChP lipid content especially correlated with ApoE4 allele carriers ( Fig. 5e ). Unexpectedly, ApoE3/ApoE3 demented AD cases also had a significantly higher rate of ChP lipid-positive areas compared with ApoE3/ ApoE3 non-dementia cases ( Fig. 5f ). We next examined whether lipid deposits in human ChPs was associated with complement proteins and inflammation. ChP lipid colocalized with C1q, ApoE, and complement C3 and C5 ( Fig. 5g and Extended Data Fig. 6a,b ). ChP lipid deposits were associated with intraluminal macrophage infiltration, very similar to mouse ApoE −/− ChPs (Extended Data Fig. 6c,d ). Factor H protein deposition was observed in both lipid-positive and lipid-negative ChPs in cases of dementia (Extended Data Fig. 6e ). A major question that arose from these data was whether the C1q-ApoE complex that we observed in vitro (Figs. 3 and 4) is also formed in vivo. C1q-ApoE complex formation was evaluated using the PLA with a resolution power of 10-30 nm, comparable to resonance energy transfer-type technologies 25 , and super-resolution stimulated emission depletion (STED) microscopy was applied in parallel ( Fig. 5h ). By PLA, we observed that the C1q-ApoE complex forms in human ChPs in vivo and that its density in ChP lipid-rich areas was higher compared with lipid-free areas (Fig. 5i ).
C1q-ApoE complexes indicate ongoing complement activity in
Aβ plaques. Complement C1q and ApoE have been observed in human AD plaques. We examined whether C1q-ApoE complexes can be observed in human AD plaques. C1q, Aβ , phosphorylated Tau (pTau), and C3 colocalized with ApoE (Extended Data Fig. 6f -h) in human brains with AD. C1q-ApoE complexes were also observed in human AD plaques ( Fig. 5j ). Moreover, Aβ -ApoE complexes but not ApoE-pTau complexes were observed in AD plaques of those with dementia ( Fig. 5j ), extending and corroborating findings that ApoE binds to Aβ but not pTau in vitro 26 . These data add to earlier reports that ApoE, C1q, and C3 are detectable in human AD plaques by demonstrating the buildup of the C1q-ApoE and Aβ -ApoE complexes in brains from AD cases with dementia. We next searched for the C1q-ApoE complex in a mouse model of cerebral β -amyloidosis (the APPPS1-21 mouse carries mutations in both the APP and presenilin genes, leading to rapid onset amyloid lesions) 27 . High-resolution 3D confocal microscopy of C1q-ApoE complexes that had been visualized with the PLA assay revealed that the complexes accumulate inside and in the immediate vicinity of methoxy-X04 + Aβ plaques in APPPS1-21 cortexes ( Fig. 5k and Supplementary Video 1), that is, the area of Aβ plaques that show plaque-associated microglia cell accumulation. Aβ -ApoE complexes were also observed in APPPS1-21 mouse brains. The majority of Aβ -ApoE complexes were located inside X04 + Aβ plaque (Extended Data Fig. 7a and Supplementary Video 2). The presence of C1q-ApoE complexes is a marker for persistent CCC activity in vivo.
We considered the possibility that liver C5 would have inflammatory effects inside the BBB, that is, the brain parenchyma, specifically in AD plaques. For this purpose, we treated APPPS1-21 mice with liver-specific C5 siRNA. C5 siRNA treatment significantly reduced serum C5 (Fig. 5i ) and the number and density of Aβ -plaqueassociated microglia cells ( Fig. 5m ) and of Aβ -plaque-associated LAMP1 (Extended Data Fig. 7b ). C5 siRNA also reduced the percentage of intermediate-sized plaque volumes, though the total (Braak & Braak) . n = 30. c-e, ChP lipid correlated with Aβ score (Thal phase), neuritic plaque score (CERAD), and ApoE4 genotype. n = 30 biologically independent samples. f, ChP lipid correlates with dementia in ApoE3 and ApoE3 carriers. ApoE3 and ApoE3 non-dementia cases (n = 10) and dementia (n = 7). g, Human ChP sections were stained for C1q (green) and C5 (red). Scale bar,100 μ m. C5 percentage of lipid-ChP and lipid+ ChP from the same case was quantified as described in Methods. Lipid-(n = 7 biologically independent samples), lipid+ (n = 7). h, STED microscopy shows colocalization of C1q (green) and ApoE (red). Scale bar, 5 μ m. i, Binding of C1q-ApoE in vivo by PLA. Anti-ApoE, anti-C1q, or no primary antibodies were used as controls. The number of C1q-ApoE complexes of lipid-ChP or lipid+ areas were quantified as described in Methods. Lipid-(n = 4 independent samples), lipid+ (n = 4). Scale bar, 5 μ m. j, Human brain sections were stained for Aβ /ApoE, pTau/ApoE, C1q/ApoE, or C1q alone. Proteinprotein binding in vivo was detected by PLA. Blue for nuclei. Scale bar, 5 μ m. k, 16- week old AD (APPPS1-21) brain cortex sections were examined using the PLA assay for the presence of C1q-ApoE complexes, with methoxy-X04 to outline plaques. X04-(n = 5), X04+ (n = 5). Scale bars, 10 µ m. l, Liver-targeted C5 siRNA reduces serum C5 in APPPS1-21 mice. Control (n = 4 mice), C5 (n = 5). m, Brain sections were stained with iba1 for microglial cells (red), To-Pro-3 for nuclei (green), and X04 for Aβ plaque (blue). White dashed circle represents the area within a 30 µ m radius. The number of iba1 + /To-Pro-3 + cells per area were quantified (> 30 µ m radius represents non-Aβ plaque area). Plaques were further grouped into small plaques (X04% < 0% of 30 µ m radius area), moderate plaques (X04% between 10 and 30% of 30 µ m radius area), and large plaques (X04% > 30% of 30 µ m radius area). Percentage of iba1 positivity within a 30 µ m radius of Aβ plaques and non-Aβ plaque areas were compared. 420 individual Aβ plaques and 40 fields of non-Aβ plaques from four control mice, 536 individual Aβ plaques and 51 fields of non-Aβ plaques from five C5-treated mice. Data in h,j are representative images from at least three independent samples. Data represent means ± s.e.m. Two-tailed Student's t test was applied to a,c,d,f; paired two-tailed Student's t-test was applied to g,i,k; one-way ANOVA was applied to e; two-way ANOVA was applied to l,m.
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plaque load was unchanged under these experimental conditions (Extended Data Fig. 7c,d) . These data show that C5 cleavage contributes to Aβ pathology. Additionally, C1q-ApoE complexes were observed in 8-week old (adolescent) WT brain cortexes (Extended Data Fig. 7e ). As the complex only forms under conditions of activated C1q (described above), these data indicate that the C1q-ApoE complex may play a physiological role in normal brain homeostasis.
C1q-ApoE complexes in atherosclerosis.
Our data raised the possibility that other unresolvable human diseases show similar pathological hallmarks that we identified in ApoE −/− ChPs in mice and human and mouse AD brains. We examined complement pathways during the early stages of atherosclerosis in ApoE −/− mice. When we mined gene expression signatures in WT versus ApoE −/− aortas 28 , we found nine complement-pathway-related transcripts (largely CCC related) to be > 2-fold upregulated during development of aortic atherosclerosis (Fig. 6a, Extended Data Fig. 8a,b and Supplementary  Table 7 ). The impact of CCC on atherosclerosis was examined by C5 siRNA treatment on ApoE −/− mice for 20 weeks (Fig. 6b ). Treatment reduced both thoracic and abdominal atherosclerosis by ~65% in the total aorta ( Fig. 6c ). C5 siRNA reduced aortic root atherosclerosis and decreased macrophage density in plaques ( Fig. 6d,e ), without affecting blood lipid levels, body weight, or blood leukocyte counts (Extended Data Fig. 8c-g) . We next evaluated C1q-ApoE complexes in human carotid atherosclerosis. Five healthy control arteries on autopsy (type 0-I; American Heart Association classification 29 ), six early (type II-III) and nine advanced atherosclerotic plaques (type V-VII) ( Supplementary Table 8 ) from carotid endarterectomy specimens were stained for CD68 + macrophages and DCs, C1q, ApoE, and C5 (Fig. 6f ). CD68 + macrophages and C1q, ApoE, and C5 protein deposits increased in early and advanced plaques compared with control arteries (Fig. 6g ). C1q and ApoE colocalized in atherosclerotic plaques, as determined by means of STED microscopy (Extended Data Fig. 8h ). The C1q-ApoE complex emerged as a marker of CCC activity in atherosclerotic plaques (Fig. 6h ). However, although both C1q and ApoE were expressed in the uninflamed media layer of human carotid atherosclerotic arterial wall, no C1q-ApoE complexes were detectable there (Fig. 6g,h) . Malondialdehyde-epitopes (MDA2) were observed on the surface of lipid deposits within plaques (Fig. 6i ).
Discussion
We identified a CCC activity-regulating C1q-ApoE complex in diseased ChPs, AD plaques, and atherosclerotic arteries. As ApoE qualifies as a checkpoint inhibitor of the CCC via formation of the C1q-ApoE complex, our data directly tie ApoE to the regulation of the immune system and identify its mechanism of action.
The CCC is triggered by activation of C1q, which can be established by multiple mechanisms in diverse sets of physiological and pathophysiological states [30] [31] [32] [33] [34] . The widespread range of C1q activators illustrates the ubiquitous actions and central position of the CCC to maintain tissue homeostasis and, more specifically, to respond to bacterial infection by activating the innate immune system 31, 32, 34 . However, inappropriate control of the CCC causes its malfunction, injurious tissue inflammation, and disease 32, 34 (Fig. 6j ). That ApoE may be indispensable for CCC regulation is indicated by the marked pathologies of the ChP and of atherosclerosis in ApoE −/− mice and by the observation that the disease burden can be reduced by C5 siRNA in peripheral tissues and the brain in experimental models as varied as ApoE −/− and APPPS1-21 mice. The salient expression of C1q-ApoE complexes in ChPs, AD plaques and atherosclerotic lesions are indicative of ongoing complement activity, suggesting multiple therapeutic targets such as the complex itself, the downstream constituents, and the corresponding receptors on immune cells 32, [34] [35] [36] [37] .
The two binding partners of the complex, C1q and ApoE, have previously been viewed as separately acting molecules 30, [38] [39] [40] [41] [42] [43] [44] [45] performing independent tasks in numerous tissue contexts (Extended Data Fig. 9a ). Indeed, in addition to being involved in bona fide complement pathways, complement constituents have recently been recognized to impact noncanonical events outside of the innate arm of the complement cascade-guided immune system, such as regulating inflammasomes or skewing the immune system 32, 34, 46 . Moreover, the Janus-headed natures of C1q and ApoE often become apparent only in distinctive tissue contexts where they are either beneficial or detrimental 30, [38] [39] [40] [41] [42] [43] [44] [45] . Our data suggest that at least some pathologies previously thought to reflect single actions of C1q or ApoE may in fact involve C1q-ApoE complexes (Extended Data Fig. 9a ). We believe that the roles of C1q-ApoE complexes in vivo deserve to be considered prudently; the in vitro data demonstrate that ApoE is a checkpoint inhibitor of CCC activity, and our genetic, pharmacological, and clinical translational studies provide evidence that the C1q-ApoE complex is also active in vivo ( Fig. 6j and Extended Data Fig. 9b ). More work is needed to further evaluate the role of the complex versus the single actions of C1q and ApoE in multiple experimental and human disease conditions. Such studies would require a better understanding not only of the domain structures of each C1q and ApoE as prototypic multidomain-binding molecules but also of the amino acid binding sequences in ApoE to form a complex with C1q. As most, if not all, chronic inflammatory diseases are associated with activation of one or more complement pathways, and C1q and ApoE are locally induced in response to multiple types of stress, our hypothesis that activated C1q initiates formation of the complex with resultant CCC-dependent physiological/beneficial or, Control (n = 11 mice), C5 siRNA (n = 12). c, En face staining for whole aorta. Scale bar, 0.5 cm. Atherosclerotic plaques were quantified, as described in Methods. Control (n = 11 mice), C5 siRNA (n = 12). d,e, Aortic root sections were stained for ORO and HE and CD68 + macrophages and DCs. Scale bare, 100 µ m. Plaque size (d) and CD68 + macrophages and DCs sizes (e) were quantified as described in Methods. Control (n = 4 mice), C5 siRNA (n = 4). f, Human carotid artery parallel sections were stained for CD68, C1q, ApoE, and C5 by DAB and hematoxylin. Representative images from g. g, CD68, C1q, ApoE, and C5 signal was quantify as described in Methods. Control (n = 5 independent samples), early plaque (n = 6), advanced plaque (n = 9). h, C1q-ApoE complexes in human atherosclerosis plaque was determined by PLA. Intima (n = 3 independent samples), media (n = 3). Scale bar, 5 μ m. i, Highresolution microscopy shows colocalization of lipid (green) and malondialdehyde epitopes (MDA2, red) in human atherosclerotic plaque. Scale bar, 10 μ m. Representative images from at least three independent samples. j, Schematic representation of the C1q-ApoE complex. Locally produced and/or serumrecruited C1q is activated in situ by a variety of surface activators including oxidized lipid, oxLDL, amyloid fibrils, and immunoglobulins. C1q activators have been implicated in diseases as varied as atherosclerosis and AD. After activation, C1q acquires an active conformation that allows initiation of the CCC, with resultant generation of C3a and C3b and C5 cleavage to generate C5a and C5b. ApoE inhibits the CCC activity by binding ApoE at high affinity to the active C1q and forms the C1q-ApoE complex (top). By contrast, inflammation is amplified in the absence of ApoE by overactivation of the CCC (bottom). C1q: inactive (yellow), activated (light green), overactivated (red). Data represent means ± s.e.m. Two-tailed Student's t test was applied to b,c,h; one-way ANOVA was applied to a,g; two-way ANOVA was applied to d,e.
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if the CCC becomes persistently activated, disease-associated inflammation, deserves future attention in both basic and clinical studies.
AD and atherosclerosis share risk factors 47 , whereas the second most common form of dementia, vascular dementia, has been closely related to LOAD. The incidence of AD is greatly enhanced in patients with both atherosclerosis and the ApoE4 allele, consistent with common mechanisms of disease progression 48 . Our suggestion that the C1q-ApoE complex forms an active disease-relevant regulatory module is consistent with the frequent occurrence of autoimmune diseases or immune deficiencies in patients afflicted with genetic absence or loss-of-function mutations in C1q, C2, C4, and other components of the CCC and with the identification of both C1q and ApoE as major players in LOAD and atherosclerosis in genetic association studies 49, 50 . 
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Methods
Mice. C57BL/6J WT and ApoE −/− mice were purchased from the Jackson Laboratories and housed in the animal facilities of Jena and Munich Universities. WT and ApoE −/− mice were fed a standard rodent chow under pathogen-free conditions. ApoE3 knock-in (ApoE3-KI) and ApoE4-KI mice on C57BL/6J background were purchased from Taconic, USA 51 and maintained in the animal facility of Jena University under mouse chow or fed a high-fat cholate-containing diet (Altromin, Germany) containing 15.8% fat, 1.25% cholesterol, and 0.5% sodium cholate. The diet was started at the age of 62 weeks and continued for 16 weeks. APPPS1-21 mice 27 were studied in collaboration with Mathias Jucker, Hertie Institute for Clinical Brain Research, University of Tübingen. Animal procedures were approved by Regierung Oberbayern according to guidelines of the local Animal Use and Care Committee and the National Animal Welfare Laws. Human brain and choroid plexus tissues. All tissues were collected and provided by the Neurobiobank Munich, Ludwig-Maximilians-University (LMU) Munich according to the guidelines, and the protocols were approved by the ethics committee of Faculty of Medicine, LMU. The ApoE genotype was determined by means of PCR (Ezway PCR kit, Koma Biotech). AD-related pathologies (neurofibrillary tangles and beta amyloid) were determined according to the guidelines of the Brain Net Europe Consortium 52, 53 , the density of neuritic plaques according to the plaque score modified from CERAD by the National Institute on Aging 54 . Patient characteristics are summarized in Supplementary Table 6 .
Human carotid artery tissues. Atherosclerotic plaques were obtained from patients with high-grade carotid artery stenosis (> 70%) 55 after carotid endarterectomy. Healthy control carotid arteries were obtained from the Forensic Medicine Institute (type 0-I) 29 . Healthy control arteries comprised all three vessel layers: intima, media, and adventitia. Atherosclerotic plaques consisted mainly of the diseased intima resulting from the surgical intervention used for plaque excision 56 . The study was performed according to the Guidelines of the World Medical Association Declaration of Helsinki. The ethics committee of Faculty of Medicine, Technical University of Munich (TUM) approved the study, and written informed consent for permission to be included into the Munich Vascular Biobank was given by all patients. The baseline patient characteristics are summarized in Supplementary Table 8 .
C5 siRNA injection. Mice were randomly separated into two groups. 5 mg/kg C5 siRNA targeting the liver (20 mg/ml in PBS) or control siRNA targeting luciferase (20 mg/ml in PBS) (provided by Alnylam Pharmaceuticals, Inc.) were administered subcutaneously every 2 weeks. Serum C5 protein levels were determined by means of ELISA. Complement C5-deficient DAB2 mouse serum (provided by Alnylam Pharmaceuticals, Inc.) was used as negative control for ELISA.
Atherosclerotic lesion analyses.
Mouse aortas were prepared and stained by Sudan-IV for en face atherosclerosis analysis, as described previously 57 . The extent of atherosclerotic plaques was quantified in total aorta, thoracic aorta, and abdominal aorta using ImageJ software. In addition, plaque sizes were quantified in oil red O-and hematoxylin-stained serial sections of aortic root. Human carotid plaques were segmented in blocks of 3 to 4 mm, fixed in formalin overnight, decalcified in 0.5 M EDTA (pH 7.2) and embedded in paraffin (FFPE), as described previously 58, 59 , or fresh frozen in Tissue-Tec (Sakura Finetek) for immunofluorescent staining of lipid. Hematoxylin-eosin and Elastic van Gieson (EvG) staining was performed to assess atherosclerosis. Specimens were divided into early (II-III) and advanced stages of atherosclerosis (V-VII). In paraffin sections, antisera were first optimized using different dilutions to determine the best staining results with minimal background. After primary antibody incubation, visualization was performed using the LSAB ChemMate Detection Kit (Dako, Denmark) according to the manufacturer's instructions. Stained slides were scanned by ScanScope microscope (Leica) to obtain digital images. All images were prepared as TIF files and quantified using imageJ software.
Histology, immunofluorescence microscopy, and morphometry. For immunofluorescence staining, tissues were dissected and embedded in Tissue-Tec (Sakura Finetek), frozen in isopentane, and stored at -80 °C. 20 μ m whole mouse brain coronal sections or one hemisphere of AD mice were prepared according to the mouse brain atlas map 60 . Human and mouse brain sections were stained for oil red O for lipid adopted from protocols for atherosclerosis (described above). Total areas of ChPs and the lipid + areas were determined using AxioVision Rel 4.6 software (Carl Zeiss) and Leica Application Suite (Leica). AD mouse brain sections were stained for Methoxy-X04 (Tocris Bioscience) for Aβ plaque. The total number of Aβ plaques per section or per brain area were quantified using Leica Application Suite (Leica). Immunofluorescence staining was performed as previously described 28 , using marker antibodies anti-mouse collagen IV (2150-1470; AbDSerotec), immunoglobulins (715-166-151; Dianova), immunoglobulin isotype that does not react with mouse Ig (017-160-006; Dianova), anti-human/mouse C3 (A213, ComplementTech), anti-human/mouse C3a (A218, ComplementTech), anti-human C5 (A220, ComplementTech), anti-mouse C5 (ab11898, Abcam), isotype for C5 (ab27478, Abcam), anti-mouse C1q (HM1096BT, Hycult Biotech), anti-human C1q (ab71089, Abcam), anti-mouse C4 (HM1046, Hycult Biotech), anti-human Factor H (A312, Quidel), anti-mouse Factor H (HM1119F, Hycult Biotech), anti-human ApoE (ab52607, Abcam), anti-human ApoE (178479; Calbiochem), anti-mouse ApoE (ab183597, Abcam), anti-mouse CD68 (FA11; Serotec), anti-human CD68 (EMB11, DAKO), anti-mouse CD31 (553370; BD PharMingen), anti-mouse iba-1 (019-19741; WAKO), anti-mouse CD45 (BZL 01145; Biozol), anti-human/mouse cytokeratin (Z0622; DAKO), anti-human collagen IV (CIV22, DAKO), anti-beta-amyloid (4G8, BioLegend), anti-phospho-Tau (AT8, Thermo Fisher), anti-iba1 (polyclonal, WAKO), anti-LAMP1 (1D4B, Abcam), TO-PRO-3 Iodide (642/661) (T3605, Thermo Fisher Scientific) or DAPI for DNA. Anti-malondialdehyde (MDA)-lysine epitope antibody was in-house produced, as described previously 17 . Secondary antibodies were used as previously described 61 . For negative controls, stainings were performed without primary antibodies or isotype controls. Stained sections were analyzed using a confocal laser scanning microscope (CLSM) 510 META (Carl Zeiss, Germany) or Leica SP8 3× (Mannheim, Germany). The numbers and areas of microglia cells (iba1+ / To-Pro-3+ cell) within 30 µ m and > 30 μ m were quantified as described previously 43 . All images were prepared as TIF files by imageJ or Leica LAS-X (V1.2) software and exported into Adobe IIIustrator CS6 for figure arrangements.
Proximity ligation assay. Protein-protein binding ex vivo was performed using Duolink PLA kit (DUO92101 SIGMA). Fresh-frozen human choroid plexus, brain parenchyma, and carotid artery sections were fixed with 4% PFA for 10 min at 4 o C, then blocked with blocking buffer for 30 min. After washing, sections were stained with rabbit anti-human ApoE (ab52607, Abcam) and mouse anti-C1q (ab71089, Abcam) or mouse anti-beta-amyloid (4G8, Biolegend), mouse anti-phospho-tau (AT8, Thermo Fisher) overnight at RT. APPPS1-21 mouse brain sections were fixed with 4 % PFA, followed with 10 min Methoxy-X04 (Tocris Bioscience) staining for Aβ plaque. After washing, sections were stained with rabbit antimouse ApoE (ab183597, Abcam) and mouse anti-C1q (HM1096BT, Hycult) with no and/or one primary antibody as controls. Apoptotic THP-1 cells (ATCC TIB-202, UV light for 2 h) were seeded onto poly-L-lysine-coated (Sigma-Aldrich, MO, USA) diagnostic slides, type PTFE (Carl Roth, Karlsruhe, Germany). Cells were incubated in NHS or C1q-depleted human serum (each 1%) (Complement Technology, TX, USA) for 30 min. Cells were blocked and treated with rabbit anti-ApoE antibody (25 µ g/ml) (Acris Antibodies, Herford, Germany) and mouse anti-C1q antibody (25 µ g/ml) (Thermo Fisher Scientific, MA, USA). PLA signal was detected with Duolink PLA kit according to manufacturer's protocol. Leica confocal microscope (SP8, Leica, Germany) equipped with a 100× oil objective (NA 1.4) or LSM 710 equipped with ZEN 2011 software were used for image. Six fields per each sample were recorded; 3D reconstructions and the number of PLA signals per volume were performed using LAS-X software package (Leica, v1.2, Germany). Fluorescence was measured on cultured single cells.
Labeling of lipid with BODIPY. Stock solutions were prepared by dissolving 1 mg BODIPY 493/503 (4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diazas-indacene; Invitrogen) in 1 ml ethanol and stored at -20 °C. Tissue sections were fixed with 3% PFA, then stained with antibodies, then with BODIPY 493/503 (1:1,000 dilution with 150 mM NaCl buffer) for 10 min at room temperature (RT) protected from ambient light, and mounted.
Stimulated emission-depletion microscopy.
For 3D STED and CLSM microscopy, samples were imaged on a Leica SP8 STED 3X microscope (Leica, Germany) equipped with a 100× oil objective (NA 1.4). A tunable white light laser source was used to excite fluorophores. Depletion was performed at 660 nm and 775 nm for Cy3 and Cy5 or Abberior STAR 635P, respectively. We applied a CLSM sequence prior to the STED sequences for recording the DAPI signal. 3D reconstructions were performed using LAS-X software package (Leica, v1.2, Germany) and ImageJ.
Transmission electron microscopy. Mice were put down by isoflurane and perfused transcardiacally for 2 min with PBS, then perfused for 8 mins with freshly prepared 4% PFA + 1% glutaraldehyde buffer under 120 mm Hg pressure. Brain tissues were immersed in cacodylate buffer and cut at 400 μ m thick sections using a Vibratome (Leica, VT1000S). After three washes with cacodylate buffer, a postfixation with 1% osmium tetroxide in cacodylate buffer was done, according to previous methods 62 . 0.5 μ m 2 sections of areas of interest were selected. 80 nm ultrathin sections were cut and stained with lead citrate and examined using an EM900 (Zeiss) TEM.
Blood-brain barrier assay. Mice were perfused with 200 ml 4 % PFA under 120 mm Hg pressure. Ig was stained with donkey anti-mouse IgG conjugated CY3 antibody. Collagen IV antisera were used to label basement membranes of blood vessels. Ig + signals located in the perivascular space were used to determine BBB integrity. For quantitative studies, cerebellum was used; three or four sections (200 μ m interval) were stained with Ig; vessels with a diameter of more than 10 μ m (representing arteries) were used.
Laser capture microscopy and generation of microarrays. LCM and microarray analyses were performed as previously reported 28, 63 . Brain sections Articles NATuRE MEDiCiNE were dissected using the PALM MicroBeam system (Carl Zeiss MicroImaging). Trizol buffer was used to lyse tissues. RNA preparation and microarrays were done as reported previously 63, 64 . cDNA was synthesized, amplified, and purified, and the probe was fragmented (0.5-12 μ g cRNA), then hybridized for 20 h in hybridization buffer according to Affymetrix protocols. Arrays were scanned immediately after staining, and raw data were scaled to 500 and exported for further analyses.
Microarray data analysis. Microarray data analyses were done as previously reported 63, 64 . Briefly, signal intensities were calculated from the raw data and scaled to an array trimmed mean of 500; R and Bioconductor were used in all further steps. Data were filtered prior to statistical analysis to remove genes with low expression or without significant changes between groups. Data were used from two groups and subjected to Student's t test. Use of data after applying filters with more than two groups were subjected to one-factor variance analysis (ANOVA). Tests with P values of P ≤ 0.01 were performed with Benjamini-Hochberg correction for multiple testing. Microarray data were deposited in the NCBI's gene expression omnibus (GEO; accession number GSE85774 and GSE85775 for ChPs, and GSE40156 for aortas 57 ). After preincubation of the proteins in NHS for 15 min at 37 °C, the NHS-protein mix was added to the erythrocytes and incubated for additional 30 min at 37 °C. Lysis of erythrocytes was determined by measuring the amount of hemoglobin in the supernatants at 414 nm. The results were calculated as hemolysis rate relative to the level of lysis in absence of ApoE; the latter was set as 100%.
Proteins and antibodies
E. coli killing assay. Different amounts of ApoE (0.1-1 µ M) together with 0.2% NHS were preincubated for 10 min at 37 °C before adding E. coli pET200/D-TOPO (1,000 cells per sample). After an incubation of 30 min at 37 °C cells were plated to a LB-agar plate and cultivated overnight at 37 °C before counting colony forming units. To distinguish which complement pathway was effected, the experiment was performed incubating ApoE3 with NHS in GVB ++ for all three pathways, with NHS in Mg-EGTA buffer for the alternative, and with C1q-depleted serum in GVB ++ for the lectin and the alternative pathways. Bacterial survival without adding ApoE was set as 10%.
Complement activation assay. The effect of ApoE on classical complement pathway C4b and C5b-9 deposition was analyzed by ELISA. The classical pathway was activated by coating either IgM (2 µ g/ml) or MDA-LDL (1 µ g/ml) to a microtiter plate. ApoE (0.25-2 µ M), Vnt (0.5 µ M) were preincubated with 1% NHS in GVB ++ buffer for 15 min at 37 °C and added to coated plates for 1 h at 37 °C. Complement activation with NHS alone was set as 100%.
Cleavage and cofactor assays. The influence of ApoE on C1s to cleave C2 and C4 was determined in fluid phase. ApoE3 (5 and 50 µ g/ml) was preincubated with C1s (20 µ g/ml) in GVB ++ buffer for 15 mins at 37 °C, then C2 (10 µ g/ml) or C4 (10 µ g/ml) for 30 mins at 37 °C. C4b cleavage activity of ApoE was determined by incubating C4b (20 µ g/ml) with ApoE3 (5 and 50 µ g/ml) or C4BP (20 µ g/ml) for 30 mins at 37 °C. C4b cleavage was followed by western blotting. Cofactor activity of ApoE was measured by incubating C4b (10 µ g/ml) with factor I (FI) (5 µ g/ml), C4BP (20 µ g/ml), ApoE3 (10 µ g/ml) or combinations thereof (FI together with C4BP and FI together with increasing amounts of ApoE3 (0.1-100 µ g/ml)) for 30 mins at 37 °C. C4b cleavage was analyzed by western blotting.
ELISA. Recombinant or plasma-purified ApoE (0.1, 0.4, or 0.5 µ M), ApoE peptides (0.1 µ M), IgM (1 µ g/ml), LDL, oxLDL, and MDA-LDL (each 1 mg/ml) or gelatin (10 µ g/ml) were immobilized in carbonate-bicarbonate buffer (Sigma) on microtiter plates (F96 Maxisorb, Nunc-Immuno module) overnight at 4 °C. After washing the plate three times with washing buffer (PBS) containing 0.1% Tween 20), wells were blocked (PBS, 1% BSA, 5% milk) for at least 1 h at 37 °C. Coated proteins were incubated for 1 h at 37 °C with C3, C3b, and C1q (0.1 µ M) or C1q (0.02-5.33 nM) or NHS (0.075-10%) in GVB ++ buffer. Calcium-dependent binding of C1q to ApoE was determined by diluting C1q in GVB ++ buffer or in PBS and adding increasing amounts of EGTA (3-12 µ M) (Sigma) with a fixed concentration of C1q (2 or 5 nM) to immobilized ApoE proteins. Binding force was analyzed incubating C1q or the LDLR (0.1 µ M) with or w/o NaCl (0.5 M) or SDS (1 %) on immobilized ApoE3. C1q, C3, and C3b binding was analyzed by specific primary antibodies and followed by HRP-conjugated secondary antibodies. The reaction was developed with TMB (Kementec Diagnostics) or 1,2-phenylenediamine dihydrochloride (OPD tablets, Dako) and the absorbance at 450 nm or 492 nm was recorded.
Competition assay. To verify binding of ApoE peptide 139-152 to C1q, different amounts of ApoE 139-152 and ApoE 30-40 as a control (6.25-100 nM) were incubated with a constant concentration of C1q (0.6 nM) on immobilized ApoE3 (0.1 µ M). Binding of C1q to ApoE3 was analyzed using specific antibodies. ELISA was performed to investigate whether ApoE competes with the C1sC1r tetramer for binding to C1q. C1q (0.6 nM) together with different amounts of the C1sC1r tetramer (1.53-100 nM) in PBS ++ were incubated with 0.1 µ M immobilized ApoE3 for 1 h at 37 °C. After a washing step, C1q binding to ApoE was determined. 20 nM C1q was incubated with increasing concentrations of LDLR (0-20 nM) to immobilized ApoE, binding of ApoE--C1q and ApoE-LDLR was followed by ELISA. Background binding of anti-C1q and anti-LDLR to immobilized ApoE was set at 0%.
Binding assays, BLItz™ and surface plasmon resonance. Biolayer interferometry (BLItz™, ForteBio) was used to examine binding of recombinant ApoE isoforms to C1, C2, C4, C1 complex components C1q, C1s, C1r, and to MBL and the binding of C1q to ApoA. Biotinylated proteins (ligands) were coupled to streptavidin-coated biosensors, and different analytes were added. Streptavidin-coated biosensors (VWR) were hydrated for 10 min in PBS with calcium and magnesium (PBS ++ , Lonza) before loading 20 µ g/ml biotinylated ApoE2, 3, and 4 or ApoA for 120 sec. After a 30 sec baseline step 45 nm of complement protein analyte was associated for 240 s to the sensor followed by a 240 sec dissociation step. For biotinylation ApoE isoforms as well as ApoA were incubated with biotin (Thermo Fisher Scientific) for 30 min at RT. Samples were separated from unbound biotin using Centri Pure Mini Spin columns (Biotech). Surface plasmon resonance was used to examine the binding of ApoE (62-1,000 nM) to C1q (immobilized to a 5 M Biacore Chip) in real time. Binding of ApoE (1,000 nM) was determined upon addition of increasing amounts of Ca 2+ chelator EGTA (0.1-3 mM) in the binding buffer (75 mM NaCl, 5 mM HEPES, 1 mM CaCl 2 ).
Affinity measurement of ApoE binding to C1q. Affinity constant (K D ), association (k on ), and dissociation (k off ) constants of ApoE binding to C1q fulllength proteins and C1s was determined by BLItz™. Streptavidin-coated biosensors were hydrated for 10 min in PBS ++ . Recombinant ApoE2, ApoE3 and ApoE4, plasma-purified ApoE3, or C1s (each 20 µ g/ml) were loaded for 120 s via biotin onto the sensor. After 30 s baseline, C1q (0.047-45.65 nM) or MBL (45.45 nM) was associated for 240 s followed by a 240 s dissociation step. Affinity values were generated by BLItz software analysis as an advanced kinetics experiment using MBL as reference value. Initial fluorescent analysis (NanoTemper) was used to determine the K D of the binding between C1q and ApoE 139-152 . Alexa 647-labeled ApoE 136-152 (10 nM) or ApoE [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] (30 nM) were incubated with different amounts of C1q (0.073-1196.8 nM) in PBS ++ for 30 min in the dark. After 10 min centrifugation, samples were transferred into standard capillaries, and initial fluorescence was measured using a Monolith NT.115Pico (LED power 60%, MST power 20%). To test whether the observed fluorescence changes are due to a binding event, an SD test was performed: the three samples with the highest and the lowest C1q concentration were centrifuged for 10 min at 15,000g before removing the supernatant and adding SD mix (4% SDS, 40 mM DTT). After an incubation step of 5 min at 95 °C samples were transferred to capillaries and initial fluorescence was measured. The initial fluorescent analysis v2.0.2 was used to determine the K D .
Coimmunoprecipitation. For coimmunoprecipitation of C1q (Invitrogen, clone 9A7) and ApoE (Invitrogen, clone 1H4), monoclonal antibodies were bound to protein G-coupled Dynabeads (Complement Technology). Beads were incubated with purified human ApoE (Merck) and/or purified C1q (Complement Technology) and/or NHS (2%) or C1q-deficient serum (dNHS, Complement Technology) (2%). NHS or anti-C1q antisera with NHS were incubated with 1 nature research | reporting summary 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data analysis
All images were prepared as TIF files by imageJ or Leica LAS-X (V1.2) software and exported into Adobe IIIustrator CD6 for figure arrangements; 3D reconstructions were performed using LAS-X software package; For microarray, signal intensities were calculated from the raw data and scaled to an array trimmed mean of 500, R and Bioconductor were used in all further steps. Data were filtered prior to statistical analysis to remove genes with low expression or without significant changes between groups. Data were used from two groups and subjected to Student´s t-test. Use of data after applying filters with more
Validation
The specificity of ApoE antibody is verified by the absence of signal in Immunofluorescence in samples from ApoE knock out mice. 
Eukaryotic cell lines
Wild animals
Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.
Field-collected samples
For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.
